A5110196286- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Mitochondrial Function and Pathology
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Esophageal and GI Pathology
- Protein Interaction Studies and Fluorescence Analysis
- Metabolism and Genetic Disorders
- Epigenetics and DNA Methylation
- RNA modifications and cancer
- Health Systems, Economic Evaluations, Quality of Life
- Drug Transport and Resistance Mechanisms
- Lipid Membrane Structure and Behavior
- Genomics and Chromatin Dynamics
- Lung Cancer Treatments and Mutations
- DNA Repair Mechanisms
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pediatric Hepatobiliary Diseases and Treatments
- Porphyrin Metabolism and Disorders
- Biochemical and Molecular Research
- Economic and Financial Impacts of Cancer
Spanish Head & Neck Cancer Cooperative Group
2018-2025
Michigan State University
1999-2000
Consejo Superior de Investigaciones Científicas
1993-2000
Universidad Autónoma de Madrid
1993-2000
Instituto de Investigaciones Biomédicas Sols-Morreale
1993-1999
BackgroundSequential nab-paclitaxel plus gemcitabine followed by modified FOLFOX-6 (oxaliplatin, leucovorin, and 5-fluorouracil) (nab-P/Gem-mFOLFOX) showed a good safety clinical profile in metastatic pancreatic ductal adenocarcinoma (mPDAC) the phase I SEQUENCE trial.MethodsThe efficacy of sequential nab-P/Gem-mFOLFOX was compared with standard (nab-P/Gem) as first-line treatment multi-institutional, randomized, open-label, II trial patients untreated mPDAC. We randomly assigned 1:1 ratio...
615 Background: Antagonism of Mouse double minute 2 homolog ( MDM2 ) can restore p53 activity and represents a novel therapeutic strategy in biliary tract cancer (BTC). We aimed to characterize the epidemiology total population versus that harbouring amplifications; potential associations other genetic alterations survival outcomes. Methods: evaluated large real-world cohort patients (pt) diagnosed with BTC from 1st January 2017 31st December 2022 Spanish RETUD registry. Next generation...
The effect of phospholipids on the trypsin-like, chymotrypsin-like and peptidylglutamyl-peptide-hydrolysing activities so-called latent form rat liver multicatalytic proteinase was studied, assaying them with following substrates: N-Cbz-ARR-4MNA (N-Cbz, N-benzyloxycarbonyl; 4MNA, 4-methoxy-beta-naphthylamide), N-Suc-LLVY-MCA (N-Suc, N-succinyl; MCA, methylcoumarin) N-Cbz-LLE-beta-NA (beta-NA, beta-naphthylamide) respectively (amino acids are shown as their one-letter symbol). For most part...
4022 Background: Sequential treatment with nab-paclitaxel, gemcitabine followed by oxaliplatin, leucovorin and 5-fluorouracil ( nab-P/Gem-mFOLFOX) have shown a good safety profile clinical activity in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously published phase I SEQUENCE trial. Methods: We compared nab-P/Gem-mFOLFOX to the standard nab-P/Gem first-line treatment, an open-label multi-institutional prospective randomised II trial patients untreated mPDAC from 14 Spanish...
The structure of the single copy gene encoding putative housekeeping isoform Drosophila melanogaster delta-aminolevulinate synthase (ALAS) has been determined. Southern and immunoblot analyses suggest that only enzyme exists in Drosophila. We have localized a critical region for promoter activity to sequence 121 base pairs contains motif is potentially recognized by factors nuclear respiratory factor-1 (NRF-1)/P3A2 family, flanked two AP4 sites. Heme inhibits expression blocking interaction...
Abstract Lessons Learned RAS- or BRAF-mutated metastatic colorectal cancers (mCRCs) progressing after first-line treatment have a poor prognosis. European and U.S. guidelines include the multikinase inhibitor regorafenib as standard option for second-line therapy beyond, based on results of randomized phase III CORRECT trial demonstrating improvement in survival. Although stopped prematurely failing to accrue, PREVIUM trial, first prospective interventional study exploring patients with mCRC...
Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined benefit of targeting epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan irinotecan-refractory patients.KRAS exon-2 patients failing prior received (6 mg/kg) (180 mg/m²) every weeks. The primary endpoint was overall response rate (ORR). Secondary endpoints included safety, progression-free survival (PFS) (OS). KRAS...